Melissa Gilbert-Ross PhD
- Department of Hematology and Medical Oncology
Assistant Professor
- (404) 712-8370
- mmgilbe@emory.edu
- Lab website
Academic Appointment
- Assistant Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine
Education
Degrees
- PhD from Stony Brook University, Stony Brook
- BS from University of Georgia, Athens
Research
Focus
-
Mechanisms of tumor progression and metastasis
The Gilbert-Ross lab is currently focused on i) the cell biologic mechanisms exploited by genetic subtypes of lung cancer and ii) preclinical and translational studies of novel lung cancer therapeutics. To accomplish this we use the model systems Drosophila melanogaster and genetically engineered mouse models (GEMMs) coupled with molecular biology and advanced microscopy.
Publications
-
Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer.
Cancer Res Volume: 84 Page(s): 3761 - 3771
11/15/2024 Authors: Koo J; Seong C-S; Parker RE; Herrera A; Dwivedi B; Arthur RA; Dinasarapu AR; Johnston HR; Claussen H; Tucker-Burden C -
Intra-tumoral YAP and TAZ heterogeneity drives collective NSCLC invasion that is targeted by SUMOylation inhibitor TAK-981.
iScience Volume: 27 Page(s): 111133
11/15/2024 Authors: Sharma R; Sharma S; Shriwas P; Mehta L; Vu AH; Mouw JK; Koo J; Huang C; Matsuk VY; Tucker-Burden C -
Live-cell invasive phenotyping uncovers the ALK2/BMP6 iron homeostasis pathway as a therapeutic vulnerability in LKB1-mutant lung cancer.
bioRxiv
06/14/2023 Authors: Koo J; Seong C-S; Parker RE; Dwivedi B; Arthur RA; Dinasarapu AR; Johnston HR; Claussen H; Tucker-Burden C; Ramalingam SS -
Evaluating antitumor activity of Escherichia coli purine nucleoside phosphorylase against head and neck patient-derived xenografts.
Cancer Rep (Hoboken) Volume: 6 Page(s): e1708
02/01/2023 Authors: Rab R; Ehrhardt A; Achyut BR; Joshi D; Gilbert-Ross M; Huang C; Floyd K; Borovjagin AV; Parker WB; Sorscher EJ -
Loss of the endocytic tumor suppressor HD-PTP phenocopies LKB1 and promotes RAS-driven oncogenesis.
bioRxiv
01/27/2023 Authors: Seong C-S; Huang C; Boese AC; Hou Y; Koo J; Mouw JK; Rupji M; Joseph G; Johnston HR; Claussen H -
YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype.
J Thorac Oncol Volume: 16 Page(s): 464 - 476
03/01/2021 Authors: Owonikoko TK; Dwivedi B; Chen Z; Zhang C; Barwick B; Ernani V; Zhang G; Gilbert-Ross M; Carlisle J; Khuri FR -
Leflunomide Suppresses the Growth of LKB1-Inactivated Tumors in the Immune-Competent Host and Attenuates Distant Cancer Metastasis.
Mol Cancer Ther Volume: 20 Page(s): 274 - 283
02/01/2021 Authors: Jin R; Liu B; Liu X; Fan Y; Peng W; Huang C; Marcus A; Sica G; Gilbert-Ross M; Liu Y -
The level of oncogenic Ras determines the malignant transformation of Lkb1 mutant tissue in vivo.
Commun Biol Volume: 4 Page(s): 142
01/29/2021 Authors: Rackley B; Seong C-S; Kiely E; Parker RE; Rupji M; Dwivedi B; Heddleston JM; Giang W; Anthony N; Chew T-L -
The conditional growth suppressor E7.25d.7 is an allele of the sterile-20 kinase misshapen.
MicroPubl Biol Volume: 2021
01/01/2021 Authors: Kiely E; Gilbert-Ross M -
High-level expression of oncogenic KRAS is required to transform LKB1 mutant tissue in vivo.
Volume: 18 Page(s): 56 - 56
05/01/2020 Authors: Rackley BB; Seong C-S; Gilbert-Ross M